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Abstract
Although lipid peroxidation has long been associated with spinal cord injury (SCI), the specific 
role of lipid peroxidation-derived byproducts such as acrolein in mediating damage remains to be 
fully understood. Acrolein, an α-β unsaturated aldehyde, is highly reactive with proteins, DNA, 
and phospholipids and is considered as a second toxic messenger that disseminates and augments 
initial free radical events. Previously, we showed that acrolein increased following traumatic SCI 
and injection of acrolein induced tissue damage. Here, we demonstrate that microinjection of 
acrolein into the thoracic spinal cord of adult rats resulted in dose-dependent tissue damage and 
functional deficits. At 24 hours (acute) after the microinjection, tissue damage, motoneuron loss, 
and spinal cord swelling were observed on sections stained with cresyl violet. Luxol fast blue 
staining further showed that acrolein injection resulted in dose-dependent demyelination. At 8 
weeks (chronic) after the microinjection, cord shrinkage, astrocyte activation, and macrophage 
infiltration were observed along with tissue damage, neuron loss, and demyelination. These 
pathological changes resulted in behavioral impairments as measured by both the Basso, Beattie, 
and Bresnahan (BBB) locomotor rating scale and grid walking analysis. Electron microscopy 
further demonstrated that acrolein induced axonal degeneration, demyelination, and macrophage 
*Corresponding author: Xiao-Ming Xu, M.D., Ph.D., Professor and Scientific Director, Spinal Cord and Brain Injury Research Group, 
Stark Neurosciences Research Institute, Department of Neurological Surgery, Indiana University School of Medicine, 950 W Walnut 
St, R-2 Building, Room 402, Indianapolis, IN 46202, Tel: (317) 274-1036; xu26@iupui.edu. *Co-corresponding author: Riyi Shi, 
M.D., Ph.D., Professor, Department of Basic Medical Sciences, College of Veterinary Medicine, Weldon School of Biomedical 
Engineering, Purdue University, West Lafayette, IN 47907-1244, Tel: 765-496-3018 Fax: 765-494-7605; riyi@purdue.edu.
#These authors contributed equally to this work.
Disclosure Statement:
No competing financial interests exist.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Neuroscience. Author manuscript; available in PMC 2017 June 21.
Published in final edited form as:
Neuroscience. 2016 June 21; 326: 84–94. doi:10.1016/j.neuroscience.2016.03.054.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
infiltration. These results, combined with our previous reports, strongly suggest that acrolein may 
play a critical causal role in the pathogenesis of SCI and that targeting acrolein could be an 
attractive strategy for repair after SCI.
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INTRODUCTION
Traumatic spinal cord injury (SCI) leads to motor and sensory dysfunction below the level of 
injury. In the United States alone there were approximately 270,000 people living with SCI 
in 2012, and an additional 12,000 new cases occur every year, most of them younger than 
age 30 years (https://www.nscisc.uab.edu) (2012). Acute SCI initiates a complex cascade of 
molecular events termed ‘secondary injury’, which leads to progressive degeneration 
ranging from early neuronal apoptosis at the lesion site to delayed degeneration of intact 
white matter tracts, and, ultimately, expansion of the initial injury (Liu et al., 1997, Liu and 
Xu, 2012). Although the etiology and pathogenesis of SCI remain to be fully understood, 
evidence has shown that reactive oxygen species (ROS) and lipid peroxidation have a 
significant role in the pathophysiology of SCI (Hall and Braughler, 1986, Hall and Springer, 
2004, Vaishnav et al., 2010, Liu and Xu, 2012). Lipid peroxidation involves free radical-
induced oxidation of polyunsaturated fatty acids in cells and membrane phospholipids at 
allylic carbons (Vaishnav et al., 2010). As a consequence of lipid peroxidation-induced 
membrane damage, peroxidized fatty acids eventually lead to aldehydic breakdown 
products, including acrolein.
Acrolein, an α, β-unsaturated aldehyde, is highly reactive with many biomolecules including 
proteins, DNA, and phospholipids (Shi et al., 2011a). As both a product of and catalyst for 
lipid peroxidation, the highly reactive α, β-unsaturated aldehyde, acrolein, induces a vicious 
cycle of oxidative stress, dramatically amplifying its effects and perpetuating cellular 
damage (Shi et al., 2011a). Furthermore, it exhibits prolonged toxicity compared to other 
oxygen radicals within the body (Esterbauer et al., 1991, Ghilarducci and Tjeerdema, 1995, 
Luo et al., 2005) lasting for days rather than seconds (Ghilarducci and Tjeerdema, 1995, 
Evans and Halliwell, 1999). Previously, we demonstrated that acrolein was significantly 
increased in guinea pig spinal cord following a controlled compression SCI (Luo et al., 
2005) and in rat spinal cord after contusive SCI (Park et al., 2014). To determine whether 
increased acrolein is sufficient to create damage in normal CNS tissue, a micro-amount of 
acrolein was injected into the rat thoracic spinal cord, which created cord tissue damage 
(Park et al., 2014). It remains unclear whether increased acrolein within the spinal cord 
could produce dose-dependent damage of tissue and loss of function. Here, we reported that 
acrolein induced significant dose-dependent damage to the spinal cord which correlated to a 
graded loss of behavioral function.
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EXPERIMENTAL PROCEDURES
Animal care and microinjection
Adult female Sprague-Dawley rats weighing 200–250 g from Harlan Laboratory 
(Indianapolis, IN) were used in this study. All animals were maintained on a 12:12 light:dark 
schedule with food and water freely available. All animal surgical procedures and 
postoperative care protocols were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals (National Research Council) and the Guidelines of the Indiana 
University School of Medicine Institutional Animal Care and Use Committee.
Animals received injections of saline, or acrolein (at two doses: 0.1 μmol or 1.0 μmol, 
Sigma, St. Louis, MO) and were kept for 24 h or 8 wk after the injection. Briefly, animals 
were anaesthetized using an intraperitoneal (IP) injection of ketamine (40 mg/kg)/xylazine 
(5 mg/kg). During the microinjection procedure, the dorsal surface of the spinal cord was 
exposed at the 10th thoracic level (T10) and was injected at 0.6 mm from the midline and a 
depth of 1.3 mm from the dorsal cord surface using a stereotaxic device with a glass 
micropipette attached to a pneumatic picopump (World Precision Instruments, Inc., Sarasota, 
FL) (Fig. 1). In all cases, 1.0 μL of solution was injected over a period of at least 5 min. 
After injection, the needle was left in place for at least 2 min to allow for diffusion into the 
surrounding tissue. Muscle incisions were closed with silk sutures, and wound clips were 
used to close the skin. After surgery, all rats were returned to cages with clean bedding and 
placed on a heat pad. Each rat was given its own cage until it regained full consciousness. 
Once conscious, all rats were housed with rats of the same injury group. Bladders were 
manually voided until full recovery of function as needed.
Behavioral Assessments
All behavioral tests were blindly performed (n=8 rats/each group) according to our previous 
publications (Liu et al., 2006, Liu et al., 2007). Basso, Beattie, and Bresnahan (BBB) 
locomotor rating scale: The BBB scale was used to assess locomotor function of animals 
following injection procedures (Basso et al., 1995). Each rat was allowed to roam freely in 
an open field and was observed for 4 min by two scorers lacking knowledge of the 
experimental groups. The BBB scale was initially performed at 24 h after the microinjection 
to assess acute effects of the injury. Subsequently, testing was conducted once a week over a 
seven-week period to detect possible chronic effects. The BBB scale ranges from 0 (no 
discernible hind limb movement) to 21 (normal movement, including coordinated gait with 
parallel paw placement of the hind limb and consistent trunk stability). Scores from 0 to 7 
show the recovery of isolated movements in the three joints (hip, knee, and ankle). Scores 
from 8 to 13 indicate the intermediate recovery phase showing stepping, paw placement, and 
forelimb-hind-limb coordination. Scores from 14 to 21 show the late phase of recovery with 
toe clearance during every step phase. BBB Scores of both assessors were averaged for each 
hind limb. For the unilateral acrolein injection, BBB scores of the ipsilateral hind limb were 
shown. No significant difference in BBB scores of the contralateral hind limb was found. 
Grid walking: The grid walking test was also used to assess hind limb locomotor deficits 
(Behrmann et al., 1992). During the test, rats were allowed to walk on a plastic mesh (3 × 3 
sq ft) containing 4.5 × 5 cm diamond holes. Total hind limb footfalls were counted by two 
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observers unaware of the experimental groups during each trial. For testing, each animal was 
placed on the grid and allowed to perform the active grid walking task for a period of 3 min. 
During this time period, the number of footfalls (fall of the hind limb, including at least the 
ankle joint, through the grid surface) was determined individually for each hind limb.
Histology and immunohistochemistry
At 24 h and 8 wk after injection, animals were perfused for histological analysis. They 
received anesthesia with ketamine (80 mg/kg)/xylazine (10 mg/kg) and transcardial 
perfusion of 0.01 M Phosphate-buffered saline (PBS) followed by 4% paraformaldehyde 
(400 mL/rat). After perfusion, a 2-cm-long piece of the spinal cord was dissected out from 
each rat and left in the same fixative for 4 h, then transferred to 30% sucrose in 0.01M PBS 
(pH7.4). Spinal cord segments containing the epicenter were isolated from each animal, 
embedded, and cut into 20 μm-thick serial transverse sections in five identical sets. Two sets 
of the sections were stained for myelin with Luxol fast blue and counterstained with Cresyl 
violet-Eosin according to our previously described protocols (Liu et al., 2006, Liu et al., 
2007). Cresyl violet-eosin stained slides were used to generate 3-dimensional 
reconstructions of spinal cord samples using an Olympus BX60 microscope equipped with a 
Neurolucida system (MicroBrightField, Colchester, VT). Spinal cord area, lesion area, grey 
matter area, and spared white matter (WM) area of the injured cord were manually traced by 
an observer and fed into a Neurolucida algorithm to estimate volumes of the given contours 
at 2,400 μm from the injury epicenter in both the rostral and the caudal directions. This 
resulted in 4,800 μm of total tissue scrutinized for 3-dimensional analysis. Luxol fast blue 
stained tissue was analyzed over the same distance using the same system. However, Luxol 
fast blue analysis included tracing only the cord area and the spared myelin area. The same 
Cresyl violet-eosin horizontal cross sections used for assessing lesion volume were used to 
count the number of ventral motoneurons in the spinal cord epicenter region at 24 h and 8 
wk (Walker et al., 2012). A horizontal line was drawn across the transverse section of spinal 
cord tissue at the level of the central canal. All ipsilateral motoneurons ventral to the 
horizontal line were manually quantified using ImageJ software. Only clearly identifiable 
motoneurons with appropriately dark and even cresyl violet stained nuclei were counted.
The other sets of sections from rats perfused at 24 h and 8 wk post-injection were 
immunostained with ectodermal dypslasia (ED1, a macrophage marker) and anti-glial 
fibrillary acidic protein (GFAP, an astrocyte marker) according to a previously described 
protocol (Liu et al., 2006, Liu et al., 2011). The primary antibodies used included the 
polyclonal rabbit anti-GFAP (1:200, Sigma), and monoclonal mouse anti-ED1 (1:100, AbD 
Serotec, Raleigh, NC). The secondary antibodies used included fluorescein-conjugated goat 
anti-rabbit (1:100; ICN Biochemicals, Aurora, OH) and rhodamine-conjugated goat anti-
mouse (1:100; ICN Biochemicals) antibodies. Hoechst 33342 (1:100) was added as a 
nuclear stain during subsequent PBS washes.
Electron microscopy
Tissue preparation for electron microscopy was described in our previous publication (Liu et 
al., 2006, Liu et al., 2011). Briefly, spinal cord segments were fixed overnight in the solution 
containing 2% glutaraldehyde and 5% sucrose in 0.1 M sodium cacodylate buffer, pH 7.4, 
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followed by 1% osmium tetroxide in the same buffer for 1 h. The tissue was embedded in 
Spurr’s epoxy resin and cured at 70°C. Observation areas were determined by transverse 
semi-thin sections (1 μm) which were first stained with a mixture of 1% toluidine blue and 
1% sodium borate. Ultra-thin sections (70–90 nm) were collected on copper mesh grids with 
600 bars per inch, subsequently counterstained with 4 % uranyl acetate in 50 % ethanol, and 
Reynolds’ lead citrate, and examined using a Philip 400 transmission electron microscope.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism software (version 6.00, La 
Jolla California USA). All data were presented as mean ± s.e.m values, and were analyzed 
by analyses of variance (ANOVA) (one-way, two-way, or repeated-measures as appropriate) 
followed by post hoc Dunnett’s or Tukey’s multiple comparison test. A p value of <0.05 was 
considered statistically significant.
RESULTS
Acrolein induced spinal cord functional impairment in a dose-dependent manner
To determine whether micro-amounts of acrolein would induce dose-dependent functional 
impairments, we microinjected acrolein (two doses at 0.1 and 1.0 μmol) into the normal 
spinal cord of adult rats and performed both BBB locomotor rating scale and grid walking 
analyses. The BBB scale is a sensitive and reliable method for detecting differences in 
locomotion across multiple injury severities after SCI (Basso et al., 1995, 1996). BBB scores 
were reduced after the injection of acrolein (Fig. 2). Clearly, as the doses of acrolein used 
increased, the BBB scores obtained decreased. At 24 h, rats that received both 0.1 and 1.0 
μmol of acrolein exhibited significantly lower BBB scores than rats that received saline 
injection. One week later, rats injected with 0.1 μmol of acrolein no longer displayed 
significantly lower BBB scores compared to saline-injected rats. The rats injected with 1.0 
μmole acrolein, however, continued to display significantly lower BBB scores for the entire 
7 week testing period. Furthermore, rats injected with 1.0 μmol acrolein had significantly 
lowered BBB scores than rats injected with 0.1 μmole of acrolein at all the time points 
studied.
Hind limb locomotor function was also assessed using grid walk testing. None of the injury 
groups displayed any significant increase in hind limb foot drops on their uninjected side 
during the testing period (Fig. 3B). However, on the injected side, acrolein injection induced 
dose-dependent foot drops (Fig. 3A). The significant difference in foot drops between the 
low dose and vehicle-treated groups was found only at 24 h post-injection. However, 
significant differences in foot drops were found between the high dose and low dose 
acrolein-treated groups and between the high dose and saline-treated groups in most time 
points (Fig. 3A).
Acrolein induced spinal cord tissue damage in a dose-dependent manner
Because we showed that microinjections of acrolein induced dose-dependent functional 
impairments, we next examined whether such microinjected acrolein also would result in 
dose-dependent tissue damage. Histological staining was visually scrutinized for abnormal 
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properties in the microinjected tissue. At 24 h, cresyl violet staining revealed moderate and 
severe damage to both the white and grey matter, as well as motoneuron loss and cord 
swelling (Fig. 4). Stereological analyses further demonstrated that volumetric tissue damage 
was significantly increased in a dose- dependent manner after microinjections of acrolein 
(Fig. 4G–J). Luxol fast blue staining showed that acrolein injection induced white matter 
demyelination in a dose-dependent manner at 24 h (Fig. 4A–C, K). Ipsilateral to 
contralateral cord ratio was determined to give a numerical approximation of swelling or 
shrinkage of microinjected cords. A significant increase in ipsilateral to contralateral cord 
ratio occurred in animals injected with 0.1 and 1.0 μmol acrolein when compared to saline at 
24 h in Cresyl Violet stained tissue (Fig. 4L), suggesting spinal cord swelling after acrolein 
injection. Motoneurons, important for motor function, were counted to gauge the level of 
acrolein injection-induced damage. A bar graph demonstrates that motor neuron loss was 
significantly increased in a dose-dependent manner at 24 h after the injection (Fig. 4M). As 
expected, no apparent tissue damage was found in rats that received saline injection (Fig. 4A 
and D).
At the 8th wk, cresyl violet staining revealed moderate and severe damage to both white and 
grey matter, loss of motoneurons and cord shrinkage after the 0.1 and 1.0 μmol acrolein 
injections (Fig. 5). A dose-dependent lesion volume (Fig. 5G–J) and white matter 
demyelination (Fig. 5A–C, K) were also detected at 8 wk after the two doses of acrolein 
injections. In contrast to 24 h after the injections, cord shrinkage was observed at 8 wk after 
the acrolein injections (Fig. 5L). A bar graph also shows that motoneuron loss was 
significantly increased in a dose-dependent manner at 8 wk after the acrolein injection (Fig. 
5M). Immunofluorescence staining revealed an increase in GFAP expression (Fig. 6A–F) 
near the lesion border and an increase in ED-1 expression (Fig. 6G–L) within the lesion site 
at 8 wk after acrolein injection, suggesting that acrolein induced reactive gliosis and 
inflammation.
Electron microscopy showed relatively healthy, myelin wrapped axons in saline injected 
animals at 24 h (Fig. 7A) and 8 wk (Fig. 7D). Injection of 0.1 μmol acrolein resulted in 
thinning of myelin (Fig. 7B) or degeneration (Fig. 7E) of axons at 24 h and 8 wk post-
injection. Injection of 1.0 μmol acrolein showed axon degeneration, large axons with thin 
myelin, and microphage infiltration at 24 h (Fig. 7C) and 8 wk (Fig. 7F) post-injection. The 
presence of large axons with thin myelin or without myelin suggests demyelination or 
myelin dysfunction.
DISCUSSION
In the present study, we show that injection of micromole acrolein into the normal spinal 
cord is sufficient to induce dose-dependent spinal cord tissue damage. This tissue pathology 
correlates well with a dose-dependent loss of behavioral function. Immunofluorescence 
staining revealed that acrolein injection directly induced gliotic response and inflammation. 
Ultrastructurally, acrolein injection induced axonal degeneration, demyelination, and 
macrophage invasion. Previously, it was reported that, following SCI, acrolein was 
significantly increased and peaked at 24 h post-injury (Luo et al., 2005, Park et al., 2014). 
Hydralazine, a known acrolein scavenger, alleviated acrolein-mediated neuronal damage in 
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vitro (Liu-Snyder et al., 2006a, Hamann et al., 2008a, Hamann et al., 2008b), and reduced 
tissue damage, and motor deficits after SCI in vivo (Park et al., 2014). Collectively, these 
results strongly indicate that acrolein may play a critical causal role in the pathogenesis of 
spinal cord secondary damage.
Acrolein, a byproduct of lipid peroxidation, is the strongest electrophile among the 
unsaturated aldehydes (Esterbauer et al., 1991, Shi et al., 2011a) and occurs at 40 times 
greater concentration than other α, β-unsaturated aldehydes such as 4-hydroxynonenal (4-
HNE) (Esterbauer et al., 1991). Although increased acrolein was observed in the injury cord 
after SCI (Luo et al., 2005), the exact concentration of acrolein within the injured spinal cord 
has not been quantified. Increasing evidence suggests that μM-mM levels of acrolein are 
likely to occur in the pathological tissue (Nardini et al., 2002, Sakata et al., 2003, Shi et al., 
2011a). For example, it has been estimated that acrolein accumulation in the hippocampus of 
human Alzheimer’s patients could reach 500 μM (Lovell et al., 2001, Hamann et al., 2008b). 
It has also been reported that acrolein-lysine adducts could reach up to 1.24 mM in human 
urine (Satoh et al., 1999). Although the knowledge of exact diffusion patterns for specific 
compounds within CNS tissue is limited, establishing a relationship between tissue volume 
and injection diffusion has been attempted. It has been estimated that a volume of 1 μL 
solution will diffuse up to a distance of 2.2 mm in any given direction measured as early as 
10 minutes after injection in brain (Myers, 1966). Based on our measurements, the diameter 
of spinal cord of living rat is measured to be about 4 mm. Therefore, the transverse area of 
spinal cord is about 12.5 mm2 (assuming the transverse area is circular). Consequently, the 
volume of spinal cord covering such distance (2.2 mm) is about 12.5 × 2.2 = 27.5 mm3 
which is equivalent to 27.5 μL. In the case of using a dosage of 0.1 μmol (in 1 μL), the 
average possible final concentration of acrolein in such area shortly after injection could be 
about 3.36 mM, with a volume dilution of 27.5 times from the original injecting volume of 1 
μL.
Due to the known limitation of currently available measuring techniques, the reported 
literature measures of acrolein concentrations in vivo are likely underestimations. For 
example, in one of the most common techniques for measuring acrolein, the detection of 
acrolein-lysine adducts, the antibody was developed to only recognize proteins bearing 
acrolein-bound lysine residues (Uchida et al., 1998). However, it is well known that acrolein 
is equally capable of attacking cysteine, histidine, and arginine moieties (Esterbauer et al., 
1991, Stevens and Maier, 2008). Actually, it has been estimated that acrolein’s affinity for 
cysteine is higher than lysine (LoPachin et al., 2008). Consequently, acrolein-lysine adducts 
may only account for a fraction of the total acrolein-protein adducts. Therefore, it is 
reasonable to speculate that the acrolein detection using antibodies that only recognize 
acrolein-lysine adducts (but not acrolein-cysteine, acrolein-arginine, or acrolein-histidine 
adducts) is an underestimation of total acrolein-protein adducts. Taken together, it is obvious 
that the concentration we used in this initial investigation is on the high end of the range 
measured in vivo. However, considering the fact that the actual acrolein concentration may 
be significantly higher than what has been measured (due to the limitation of the current 
methods), it is possible that the concentration we used during this exploratory study may be 
closer to reality than it appears. In addition, it is worth mentioning that the toxicity of 
acrolein is time-dependent, and acrolein is likely to be present for long periods of time (on 
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the order of weeks post-injury) in physiologically compromised tissue, such as that found in 
the mechanically injured spinal cord (Park et al., 2014). However, in the current study 
examining its immediate damage in healthy tissue, the spinal cord was exposed to acrolein 
for a much shorter time. Therefore, the present experimental design may justify the usage of 
high dosage of acrolein aiming to recapitulate acrolein-mediated damage in vivo. In future 
studies, it may be a useful endeavor to gradually infuse lower acrolein loads over an 
extended time period.
One fact that further supports the relevance of the dosage of acrolein used in this 
investigation is that, acrolein microinjection with selected low and high dose induced injury 
pathology and functional deficits similar to what we observed after a classical spinal cord 
injury (Liu et al., 2006, Liu et al., 2007, Park et al., 2014). To our knowledge, this is the first 
time that dose-dependent tissue damage and functional impairment was observed after single 
injections of acrolein into the normal adult rat spinal cord. This suggests that acrolein alone 
is sufficient to induce spinal cord damage, a process similar to what we observed after a 
mechanical trauma to the spinal cord within which high levels of acrolein are found.
The acrolein injection caused significant diffusive injury in the spinal cord as shown in 
Figures 4 (G–I) and 5 (G–I). The rostral and caudal diffusion of tissue injury instigated by 
acrolein was demonstrated first in Figure 4 (24 hours post injection), and to a greater extent, 
in Figure 5 (8 weeks post injection). A further point worth mentioning here is that the 
diffusive and regenerative injury caused by acrolein in the current study is, if different than 
in SCI, an underestimation compared to in vivo SCI. This is because acrolein injury can be 
synergistically exacerbated or fueled by other parallel injuries seen in SCI (Peasley and Shi, 
2003). In the current proof-of-principle experiment, acrolein was the only pathological 
initiating factor and no physical impact was imparted onto the spinal cord. Therefore, it is 
reasonable to speculate that acrolein-mediated injury seen in the current study would be 
significantly more severe, diffusive, regenerative, and long lasting if combined with 
concomitant physical trauma and other secondary injury factors.
A noteworthy finding of this study is that acrolein injection induced spinal cord motor 
neuron loss in which acrolein was used as the only source of a damage factor. Given that 
SCI induces a rapid increase and prolonged concentration of acrolein (Luo et al., 2005) and 
that acrolein is highly reactive with proteins, DNA, and phospholipids (Shi et al., 2011a), it 
is conceivable that increased levels of acrolein may directly induce neuronal death. This is 
supported by the observation that the acrolein induced death of cultured PC12 cells, dorsal 
root ganglion cells and hippocampal neurons (Lovell et al., 2001, Liu-Snyder et al., 2006a, 
Liu-Snyder et al., 2006b). In addition to its direct effect on neuronal death, acrolein may 
trigger a cascade of downstream events, which lead to indirect neuronal death. Indeed, both 
previous and current studies demonstrated that acrolein could induce inflammation and 
PLA2 activation (Fukuda et al., 1999, Park and Taniguchi, 2008) which, in turn, induce 
neuronal death indirectly (Liu et al., 2006, Liu et al., 2007, Liu and Xu, 2012). Thus, 
acrolein likely serves as a key molecule that mediates neuronal death in both direct and 
indirect manners.
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In this study, more ventral motoneurons were found at multiple distances from the injury 
epicenter in the 8 wk post-injury group than the 24 h post-injury group in cresyl violet-
stained sections. The presence of more ventral motoneurons at the 8 wk time point does not 
necessarily mean that these neurons were regenerated. Rather, they might represent a 
population of neurons that transiently lost Nissl substances in response to an acute injury (24 
h). The Nissl substance, composed of fragments of endoplasmic reticulum with adhering 
ribosomes that are the staining target for cresyl violet, may have been denatured at 24 h, 
which made those motoneurons invisible at this time point. At 8 wk post-injury (Figure 5), 
those motoneurons which have not undergone degeneration and truly have disappeared may 
have recovered sufficiently to become visible again in regards to cresyl violet staining, as 
well as regaining their function as judged by recovery of their BBB scores and fewer foot 
drops.
Another noteworthy observation in this study was that acrolein injection induced a rapid and 
confined demyelination. This is evidenced by the lack of myelin staining in the ventrolateral 
white matter surrounding the injection site, the reduction of myelinated axons in the same 
region, and the presence of a large quantity of axons with thin myelin at the EM level. These 
results, along with the observation that acrolein can cause significant myelin damage in 
isolated guinea pig spinal cord (Shi et al., 2011b), collectively imply that acrolein is a 
molecule that could induce CNS demyelination. Based on the degradation of myelin basic 
protein observed in our previous study at the paranodal region (Shi et al., 2011b), it is likely 
that acrolein reacts directly with myelin basic protein, which leads to myelin damage 
(Readhead et al., 1990, Boggs, 2006). It remains unclear, however, whether this 
demyelination results from a direct attack of acrolein on the CNS myelin or an indirect 
effect caused by acrolein-mediated PLA2 activation and macrophage invasion. Myelin 
damage can lead to the loss of axonal conduction and paralysis in SCI (Blight, 1985, 1991, 
Totoiu and Keirstead, 2005).
Reactive gliosis and inflammation have been considered as two major characteristics of SCI. 
Our observation that acrolein-induced astrocyte reaction and macrophage invasion in the 
spinal cord further indicates that acrolein is involved in the secondary injury after SCI.
In conclusion, our study demonstrates that acrolein induced dose-dependent spinal cord 
tissue damage with astrocytic gliotic response and macrophage invasion. Such tissue damage 
was accompanied by corresponding functional impairment in a dose-dependent manner. 
These findings suggest that acrolein may play a critical causal role in the pathogenesis of 
spinal cord injury. Furthermore, the molecular mechanisms underlying the action of acrolein 
and its regulation after SCI need to be elucidated. Experiments along these lines are 
currently in progress in our laboratory.
Acknowledgments
We thank Tom Verhovshek for technical assistance and Ms. Patti Raley, a medical editor, for her critical reading of 
the manuscript. This work was supported by NIH NS073636 (RS/XMX), NS059622, DOD CDMRP 
W81XWH-12-1-0562, DVA 1I01BX002356-01A1, Craig H Neilsen Foundation 296749, Indiana Spinal Cord and 
Brain Injury Research Foundation and Mari Hulman George Endowment Funds (XMX), and by the State of Indiana 
(ISDH, Grant # A70-2-079609, A70-9-079138 and A70-5-0791033; NKL). We are grateful for the use of the Core 
Gianaris et al. Page 9
Neuroscience. Author manuscript; available in PMC 2017 June 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
facility of the Spinal Cord and Brain Injury Research Group/Stark Neurosciences Research Institute at Indiana 
University.
Abbreviations
SCI spinal cord injury
BBB Basso, Beattie, and Bresnahan locomotor rating scale
IP intraperitoneal
GFAP anti-glial fibrillary acidic protein
ED1 ectodermal dysplasia
ANOVA analysis of variance
PBS Phosphate-buffered saline
References
1. Spinal cord injury facts and figures at a glance. J Spinal Cord Med. 2012; 35:480–481. [PubMed: 
23318031] 
2. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field 
testing in rats. J Neurotrauma. 1995; 12:1–21. [PubMed: 7783230] 
3. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal 
cord contusion using the NYU weight-drop device versus transection. Exp Neurol. 1996; 139:244–
256. [PubMed: 8654527] 
4. Behrmann DL, Bresnahan JC, Beattie MS, Shah BR. Spinal cord injury produced by consistent 
mechanical displacement of the cord in rats: behavioral and histologic analysis. J Neurotrauma. 
1992; 9:197–217. [PubMed: 1474608] 
5. Blight AR. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage 
in spinal cord injury. Cent Nerv Syst Trauma. 1985; 2:299–315. [PubMed: 3836014] 
6. Blight AR. Morphometric analysis of a model of spinal cord injury in guinea pigs, with behavioral 
evidence of delayed secondary pathology. J Neurol Sci. 1991; 103:156–171. [PubMed: 1880533] 
7. Boggs JM. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci. 2006; 63:1945–1961. 
[PubMed: 16794783] 
8. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, 
malonaldehyde and related aldehydes. Free Radic Biol Med. 1991; 11:81–128. [PubMed: 1937131] 
9. Evans P, Halliwell B. Free radicals and hearing. Cause, consequence, and criteria. Ann N Y Acad 
Sci. 1999; 884:19–40. [PubMed: 10842581] 
10. Fukuda T, Kim DK, Chin MR, Hales CA, Bonventre JV. Increased group IV cytosolic 
phospholipase A2 activity in lungs of sheep after smoke inhalation injury. Am J Physiol. 1999; 
277:L533–542. [PubMed: 10484460] 
11. Ghilarducci DP, Tjeerdema RS. Fate and effects of acrolein. Rev Environ Contam Toxicol. 1995; 
144:95–146. [PubMed: 8599034] 
12. Hall ED, Braughler JM. Role of lipid peroxidation in post-traumatic spinal cord degeneration: a 
review. Cent Nerv Syst Trauma. 1986; 3:281–294. [PubMed: 3555850] 
13. Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx. 2004; 
1:80–100. [PubMed: 15717009] 
14. Hamann K, Durkes A, Ouyang H, Uchida K, Pond A, Shi R. Critical role of acrolein in secondary 
injury following ex vivo spinal cord trauma. J Neurochem. 2008a; 107:712–721. [PubMed: 
18710419] 
Gianaris et al. Page 10
Neuroscience. Author manuscript; available in PMC 2017 June 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Hamann K, Nehrt G, Ouyang H, Duerstock B, Shi R. Hydralazine inhibits compression and 
acrolein-mediated injuries in ex vivo spinal cord. J Neurochem. 2008b; 104:708–718. [PubMed: 
17995940] 
16. Liu-Snyder P, Borgens RB, Shi R. Hydralazine rescues PC12 cells from acrolein-mediated death. J 
Neurosci Res. 2006a; 84:219–227. [PubMed: 16619236] 
17. Liu-Snyder P, McNally H, Shi R, Borgens RB. Acrolein-mediated mechanisms of neuronal death. J 
Neurosci Res. 2006b; 84:209–218. [PubMed: 16619238] 
18. Liu NK, Titsworth WL, Zhang YP, Xhafa AI, Shields CB, Xu XM. Characterizing phospholipase 
A2-induced spinal cord injury-a comparison with contusive spinal cord injury in adult rats. Transl 
Stroke Res. 2011; 2:608–618. [PubMed: 23585818] 
19. Liu NK, Xu XM. Neuroprotection and its molecular mechanism following spinal cord injury. 
Neural regeneration research. 2012; 7:2051–2062. [PubMed: 25624837] 
20. Liu NK, Zhang YP, Han S, Pei J, Xu LY, Lu PH, Shields CB, Xu XM. Annexin A1 reduces 
inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in 
adult rats following spinal cord injury. J Neuropathol Exp Neurol. 2007; 66:932–943. [PubMed: 
17917587] 
21. Liu NK, Zhang YP, Titsworth WL, Jiang X, Han S, Lu PH, Shields CB, Xu XM. A novel role of 
phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol. 2006; 59:606–619. 
[PubMed: 16498630] 
22. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, Jacquin MF, 
Hsu CY, Choi DW. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci. 
1997; 17:5395–5406. [PubMed: 9204923] 
23. LoPachin RM, Barber DS, Gavin T. Molecular mechanisms of the conjugated alpha,beta-
unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases. 
Toxicol Sci. 2008; 104:235–249. [PubMed: 18083715] 
24. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer’s disease brain and is 
toxic to primary hippocampal cultures. Neurobiol Aging. 2001; 22:187–194. [PubMed: 11182468] 
25. Luo J, Uchida K, Shi R. Accumulation of acrolein-protein adducts after traumatic spinal cord 
injury. Neurochem Res. 2005; 30:291–295. [PubMed: 16018572] 
26. Myers RD. Injection of Solutions into Cerebral Tissue: Relation between Volume and Diffusioff. 
Physiol Behav. 1966; 1:171–174.
27. Nardini M, Finkelstein EI, Reddy S, Valacchi G, Traber M, Cross CE, van der Vliet A. Acrolein-
induced cytotoxicity in cultured human bronchial epithelial cells. Modulation by alpha-tocopherol 
and ascorbic acid. Toxicology. 2002; 170:173–185. [PubMed: 11788155] 
28. Park J, Zheng L, Marquis A, Walls M, Duerstock B, Pond A, Vega-Alvarez S, Wang H, Ouyang Z, 
Shi R. Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-
mediated damage. J Neurochem. 2014; 129:339–349. [PubMed: 24286176] 
29. Park YS, Taniguchi N. Acrolein induces inflammatory response underlying endothelial 
dysfunction: a risk factor for atherosclerosis. Ann N Y Acad Sci. 2008; 1126:185–189. [PubMed: 
18448814] 
30. Peasley MA, Shi R. Ischemic insult exacerbates acrolein-induced conduction loss and axonal 
membrane disruption in guinea pig spinal cord white matter. J Neurol Sci. 2003; 216:23–32. 
[PubMed: 14607299] 
31. Readhead C, Takasashi N, Shine HD, Saavedra R, Sidman R, Hood L. Role of myelin basic protein 
in the formation of central nervous system myelin. Ann N Y Acad Sci. 1990; 605:280–285. 
[PubMed: 1702601] 
32. Sakata K, Kashiwagi K, Sharmin S, Ueda S, Irie Y, Murotani N, Igarashi K. Increase in putrescine, 
amine oxidase, and acrolein in plasma of renal failure patients. Biochem Biophys Res Commun. 
2003; 305:143–149. [PubMed: 12732208] 
33. Satoh K, Yamada S, Koike Y, Igarashi Y, Toyokuni S, Kumano T, Takahata T, Hayakari M, 
Tsuchida S, Uchida K. A 1-hour enzyme-linked immunosorbent assay for quantitation of acrolein- 
and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Anal Biochem. 
1999; 270:323–328. [PubMed: 10334850] 
Gianaris et al. Page 11
Neuroscience. Author manuscript; available in PMC 2017 June 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
34. Shi R, Rickett T, Sun W. Acrolein-mediated injury in nervous system trauma and diseases. Mol 
Nutr Food Res. 2011a; 55:1320–1331. [PubMed: 21823221] 
35. Shi Y, Sun W, McBride JJ, Cheng JX, Shi R. Acrolein induces myelin damage in mammalian 
spinal cord. J Neurochem. 2011b; 117:554–564. [PubMed: 21352229] 
36. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to 
human health and disease. Mol Nutr Food Res. 2008; 52:7–25. [PubMed: 18203133] 
37. Totoiu MO, Keirstead HS. Spinal cord injury is accompanied by chronic progressive 
demyelination. The Journal of comparative neurology. 2005; 486:373–383. [PubMed: 15846782] 
38. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi 
N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad 
Sci U S A. 1998; 95:4882–4887. [PubMed: 9560197] 
39. Vaishnav RA, Singh IN, Miller DM, Hall ED. Lipid peroxidation-derived reactive aldehydes 
directly and differentially impair spinal cord and brain mitochondrial function. J Neurotrauma. 
2010; 27:1311–1320. [PubMed: 20392143] 
40. Walker CL, Walker MJ, Liu NK, Risberg EC, Gao X, Chen J, Xu XM. Systemic 
bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following 
cervical spinal cord injury. PLoS One. 2012; 7:e30012. [PubMed: 22253859] 
Gianaris et al. Page 12
Neuroscience. Author manuscript; available in PMC 2017 June 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• Acrolein microinjection produces dose-dependent tissue damage and motor 
deficits.
• Acrolein microinjection induces gliotic response and macrophage invasion.
• Acrolein could be an important contributor to secondary spinal cord injury.
• Acrolein could be a target for therapeutic intervention.
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Figure 1. 
Diagram of microinjection and experimental timeline. Saline or acrolein was injected into 
the rat spinal cord at a depth of 1.3 mm and a distance of 0.6 mm lateral from the midline at 
T10. Basso, Beattie, and Bresnahan (BBB) locomotor rating scale and grid walking tests 
were performed prior to the injection procedure, 24 h after injection, and then once a week 
for 7 wk. Animals were sacrificed at 24 h (acute observation) and 8 wk (chronic 
observation), respectively, after the injection.
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Figure 2. 
Basso, Beattie, and Bresnahan (BBB) locomotor rating scale score over 7 wk after injections 
of acrolein into the normal spinal cord of adult rats. The BBB locomotion rating scale 
showed that BBB scores decreased in response to increased doses of acrolein (**: p<0.01, vs 
saline; #: p<0.05, ##: p<0.01, vs 0.1μmol acrolein).
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Figure 3. 
Foot drops via grid walking test over 7 wk after injections of acrolein into the normal adult 
rat spinal cord on the right side at T10. (A) Significant increases of foot drops on the side 
ipsilateral to the acrolein injection were found in both doses (0.1 and 1.0 μmol) at 24 h after 
the injection. At most time points (except for the 4th wk), injection of high dose acrolein (1.0 
μmol) resulted in significantly greater foot drops on the injury side than the low dose (0.1 
μmol) or saline control (*: p<0.05,**: p<0.01, vs saline; #: p<0.05, vs 0.1μmol acrolein). (B) 
The foot drops on the side contralateral to the injection showed no difference amongst 
groups.
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Figure 4. 
Acrolein induced graded tissue damage at 24 h after injection. (A, D) Luxol fast blue (A) 
and Cresyl violet-eosin (D) stainings show no tissue damage or demyelination in a saline-
injected spinal cord. (B, C, E, F) Low (0.1 μmol, B, E) and high dose (1.0 μmol, C, F) 
acrolein injections induced a confined lesion and demyelination in the ventral and 
ventrolateral grey and white matter. Bars: A–F, 500 μm. (G–I) Representative three-
dimensional reconstruction of a spinal cord segment from each group illustrates rostrocaudal 
extension of the lesion (red). (J–L) Bar graphs show acrolein injection induced percent 
changes in lesion volume (J), demyelination (K), and cord swelling (L) among the three 
groups (Low, 0.1 μmol acrolein; High, 1.0 μmol acrolein; *: p<0.05,**: p<0.01, vs saline). 
(M) Acrolein injections into the right spinal cord cause significant dose-related motoneuron 
loss (*: p<0.05, **: p<0.01, vs saline; ##: p<0.01, vs 0.1μmol acrolein).
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Figure 5. 
Injections of acrolein into the normal spinal cord resulted in tissue damage in a dose-
dependent manner at 8 wk. (A, D) Luxol fast blue (A) and Cresyl violet-eosin (D) stainings 
showed no tissue damage or demyelination in a saline-injected spinal cord. (B, C, E, F) Low 
(0.1 μmol, B, E) and high dose (1.0 μmol, C, F) acrolein injections induced a confined lesion 
and demyelination in the ventral and ventrolateral grey and white matter. Bars: A–F, 500 μm. 
(G–I) Representative three-dimensional reconstruction of a spinal cord segment from each 
group illustrates rostrocaudal extension of the lesion (red). (J–L) Bar graphs show acrolein 
injection induced percent changes in lesion volume (J), demyelination (K), and cord 
swelling (L) among the three groups (Low, 0.1 μmol acrolein; High, 1.0 μmol acrolein; *: 
p<0.05,**: p<0.01, vs saline; ##: p<0.01, vs 0.1 μmole acrolein). (M) Acrolein injections 
into the right spinal cord caused significant dose-related motoneuron loss (*: p<0.05, **: 
p<0.01, vs saline; #: p<0.05, ##: p<0.01, vs 0.1 μmole acrolein).
Gianaris et al. Page 18
Neuroscience. Author manuscript; available in PMC 2017 June 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Immunofluorescence staining at 8th wk after acrolein injection. (A–F) Increased GFAP 
expression at the lesion border shows acrolein-induced reactive gliosis in both low (0.1 
μmol) and high (1.0 μmol) doses of acrolein injection groups. (D–F) High magnification of 
boxed areas in A-C shows normal (D) and reactive (E, F, arrows) astrocytes. Within the 
lesion epicenter, non-specifically labeled, morphologically characteristic of macrophages 
were also found (F, arrowheads). (G–I) Representative photomicrographs show increased 
ED-1 expression, a macrophage marker, within the lesion site of low and high doses of 
acrolein injections. (J–L) High magnification of boxed areas of G–I showed the lack of (J) 
or presence of (K, L, arrows) macrophages stained with ED-1 after saline (J) or acrolein (K, 
L) injections. The invaded macrophages were confined mainly within the lesion site. Bars: 
A–C and G–I, 500 μm; D–F and J–L, 40 μm.
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Figure 7. 
Electron micrographs after acrolein injection. Representative photographs of electron 
microscopic images show normal appearance of axons and myelin at 24 h and 8 wk after 
saline injection (A, D). Low and high dose of acrolein injection, 0.1 μmol and 1.0 μmol, 
respectively, induced axon-myelin pathology including large axon with thin myelin (B, F, 
double arrows), axon degeneration (C, arrows), axon and myelin degeneration (E, arrows), 
and macrophage engulfment of degenerated cell debris (F, arrow head) at 24 h (A–C) and 8 
wk (D–F) after acrolein injection. Bar = 6 μm.
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